((5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a-propyl-1h-fluoren-7-yl)oxy)acetic acid profile

You're asking about a compound with a very specific chemical name: **((5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a-propyl-1H-fluoren-7-yl)oxy)acetic acid**. This is a complex organic molecule, and understanding its importance requires delving into its potential uses and properties.

**Here's what we can glean from the chemical name:**

* **Structure:** The name hints at a complex structure with a fluorene core (a bicyclic aromatic system), substituted with various functional groups:
* **Dichloro:** Two chlorine atoms are attached to the fluorene ring.
* **Tetrahydro:** The fluorene ring system contains four hydrogen atoms, indicating partial saturation.
* **Oxo:** A carbonyl group (C=O) is present, likely on the ring.
* **Propyl:** A three-carbon alkyl chain (propyl) is attached to the fluorene ring.
* **(Oxy)acetic acid:** A -CH2COOH (acetic acid) group is attached through an oxygen atom.

**Potential Applications and Importance in Research:**

* **Pharmaceutical Research:** Compounds with this kind of structure could potentially exhibit biological activity due to their complex chemical features. They might act as:
* **Drug Candidates:** The specific arrangement of functional groups could influence their interactions with biological targets, leading to therapeutic effects.
* **Lead Compounds:** They could serve as starting points for the development of new drugs.

* **Materials Science:** Similar structures are found in polymers and plastics. The presence of chlorine atoms and the acetic acid group could influence the physical properties of the compound, such as its melting point, solubility, and potential use in materials applications.

* **Organic Chemistry:** The compound itself could be a target for synthesis and study in organic chemistry. Scientists might explore its reactivity, stability, and potential for creating new, more complex organic molecules.

**To understand its true importance, you'd need more specific information:**

* **Biological Activity:** Has the compound been tested for any biological activity? If so, what is it?
* **Synthesis and Characterization:** How is the compound synthesized and characterized?
* **Research Objectives:** What is the specific research goal in using this compound?

Without this additional context, it's difficult to definitively state the importance of this particular compound. However, based on its chemical structure, it has the potential to be relevant in various scientific fields.

L 644711: RN given refers to (R)-isomer; structure given in first source; HCO3(-)/Cl(-) antiporter antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	3035014
SCHEMBL ID	1888816
MeSH ID	M0151262

Synonym
l 644711
2-[[(8ar)-3,4-dichloro-6-oxo-8a-propyl-8,9-dihydro-7h-fluoren-2-yl]oxy]acetic acid
SCHEMBL1888816
((5,6-dichloro-9a-n-propyl-2,3,9,9a-tetrahydro-3-oxo-1h-fluren-7-yl)oxy)acetic acid
l-644,711
unii-sc0y88002k
acetic acid, ((5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a-propyl-1h-fluoren-7-yl)oxy)-, (r)-
b-3(+)
((5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a-propyl-1h-fluoren-7-yl)oxy)acetic acid
acetic acid, (((9ar)-5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a-propyl-1h-fluoren-7-yl)oxy)-
81997-33-3
dpofa
sc0y88002k ,
l-644711
acetic acid, (((9ar)-5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a-propyl- 1h-fluoren-7-yl)oxy)-
((5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a-propyl-1h-fluoren-7-yl)oxy)acetic acid, d-
DTXSID10231500
l-644-711
(r)-2-((5,6-dichloro-3-oxo-9a-propyl-2,3,9,9a-tetrahydro-1h-fluoren-7-yl)oxy)acetic acid
Q27289137
AKOS040745980

Excerpt	Relevance	Reference
" The dose of drug given intracisternally was at least 175 times less than the dosage we previously found was needed to achieve a comparable effect when the drug was given intravenously."	( Improved recovery from a traumatic-hypoxic brain injury in cats by intracisternal injection of an anion transport inhibitor. Cragoe, EJ; Kimelberg, HK; Nelson, LR; Pietruszkiewicz, AM; Popp, AJ; Rose, JW; Szarowski, D; Woltersdorf, OW, 1987)	0.27

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	5 (26.32)	18.7374
1990's	11 (57.89)	18.2507
2000's	2 (10.53)	29.6817
2010's	1 (5.26)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (5.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	19 (95.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	2.67	3	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
taurine [no description available]	1.98	1	amino sulfonic acid; zwitterion	antioxidant; Escherichia coli metabolite; glycine receptor agonist; human metabolite; mouse metabolite; nutrient; radical scavenger; Saccharomyces cerevisiae metabolite
5-(n,n-hexamethylene)amiloride 5-(N,N-hexamethylene)amiloride: inhibitor of Na+-H+ exchange; has anti-HIV-1 activity. 5-(N,N-hexamethylene)amiloride : A member of the class of pyrazines that is amiloride in which the two amino hydrogens at position N-5 are replaced by a hexamethylene moiety, resulting in the formation of an azepane ring.	1.98	1	aromatic amine; azepanes; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines	antineoplastic agent; apoptosis inducer; odorant receptor antagonist; sodium channel blocker
pentetic acid Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.	1.97	1	pentacarboxylic acid	copper chelator
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	1.98	1	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
phenelzine Phenelzine: One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.	1.97	1	primary amine
isoflurane Isoflurane: A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.	1.97	1	organofluorine compound	inhalation anaesthetic
tyramine [no description available]	1.97	1	monoamine molecular messenger; primary amino compound; tyramines	EC 3.1.1.8 (cholinesterase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter
aspartic acid Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.	2.68	3	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
cyclopentane Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.	2.04	1	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
triphenyltetrazolium triphenyltetrazolium: RN given refers to parent cpd. 2,3,5-triphenyltetrazolium : An organic cation that is tetrazole carrying three phenyl substituents at positions 2, 3 and 5.	2.04	1	organic cation
amiloride Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.	1.98	1	aromatic amine; guanidines; organochlorine compound; pyrazines	diuretic; sodium channel blocker
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	3.09	5	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
u 74006f tirilazad: a lazaroid; potent inhibitor of iron-dependent lipid peroxidation; has shown excellent activity in in vivo models of experimental central nervous system trauma & ischemia; structure given in first source; tradename Freedox	1.99	1	corticosteroid hormone
technetium tc 99m pentetate Technetium Tc 99m Pentetate: A technetium imaging agent used in renal scintigraphy, computed tomography, lung ventilation imaging, gastrointestinal scintigraphy, and many other procedures which employ radionuclide imaging agents.	1.97	1
ouabain Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.	2.38	2	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite
tamoxifen [no description available]	2.02	1	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid: A non-penetrating amino reagent (commonly called SITS) which acts as an inhibitor of anion transport in erythrocytes and other cells.	2.38	2	stilbenoid

Condition	Relationship Strength	Studies
Apoplexy [description not available]	2.02	1
Acute Brain Injuries [description not available]	2.89	4
Anasarca [description not available]	2.39	2
Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.	2.89	4
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	2.39	2
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	2.02	1
Cerebral Infarction, Middle Cerebral Artery [description not available]	2.04	1
Anterior Cerebral Circulation Infarction [description not available]	2.04	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	4	5
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	2.04	1
Brain Infarction Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis.	2.04	1
Animal Mammary Carcinoma [description not available]	1.98	1
Brain Vascular Disorders [description not available]	3.59	3
Cerebrovascular Disorders A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.	3.59	3
Thromboembolism Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.	1.99	1
Central Nervous System Disease [description not available]	2.89	1
Allergic Encephalomyelitis [description not available]	2.89	1
Craniocerebral Injuries [description not available]	2.89	1
Central Nervous System Diseases Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.	2.89	1
Craniocerebral Trauma Traumatic injuries involving the cranium and intracranial structures (i.e., BRAIN; CRANIAL NERVES; MENINGES; and other structures). Injuries may be classified by whether or not the skull is penetrated (i.e., penetrating vs. nonpenetrating) or whether there is an associated hemorrhage.	2.89	1
Cerebral Ischemia [description not available]	2.38	2
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	2.38	2
Brain Embolism and Thrombosis [description not available]	1.98	1
Anoxia, Brain [description not available]	1.97	1
Brain Swelling [description not available]	2.37	2
Brain Edema Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)	2.37	2
Hyponatremia Deficiency of sodium in the blood; salt depletion. (Dorland, 27th ed)	1.97	1
Coma A profound state of unconsciousness associated with depressed cerebral activity from which the individual cannot be aroused. Coma generally occurs when there is dysfunction or injury involving both cerebral hemispheres or the brain stem RETICULAR FORMATION.	1.97	1
Anoxemia [description not available]	2.37	2
Brain Disorders [description not available]	2.37	2
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	2.37	2
Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.	2.37	2

((5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a-propyl-1h-fluoren-7-yl)oxy)acetic acid

Description

Cross-References

Synonyms (21)

Research Excerpts

Dosage Studied

Research

Studies (19)

Market Indicators

Research Demand Index: 11.40

Study Types